
AbbVie Inc.
AbbVie Inc. (ABBV) Free Cash Flow & Analysis
Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.
ABBV · free cash flow · updated Jun 8, 2026
Core FCF metrics
ABBV · FCF · TTM · margin & CAGRFree cash flow was $17.82B for FY2025 (fiscal year ending 2025-12-31), down 0.1% year-over-year The FCF margin was 29.1%. Five-year CAGR stands at +1.2%.
Annual free cash flow history
Annual free cash flow data
FCF valuation metrics
ABBV · P/FCF · FCF yield · FCF per shareAbbVie Inc. (ABBV) trades at a FCF yield of 5.20% and a price-to-free-cash-flow ratio of 19.4x. FCF per share stands at $11.72, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.
Cash flow statement summary
ABBV · cash flow statement · operating / investing / financingFor FY2025, AbbVie Inc. generated $19.03B in operating cash flow and spent 1.21B in capital expenditures, yielding $17.82B in free cash flow.
For the complete Operating / Investing / Financing line-item breakdown:
View Full Cash Flow Statement →Free cash flow vs peers (Healthcare)
About Free Cash Flow & Methodology
AbbVie Inc. (ABBV) reported free cash flow of $17.82B for FY2025 (fiscal year ending 2025-12-31), down 0.1% year-over-year. The FCF margin was 29.1%.
Based on available data, AbbVie Inc. has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $24.25B in FY2022. The 5-year CAGR stands at +1.2%.
AbbVie Inc.'s FCF yield is 5.20% and price-to-FCF ratio is 19.4x for FY2025, based on the latest available data.
Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.
Frequently asked questions
ABBV free cash flow · 8 questionsAbbVie Inc. free cash flow was $17.82B for FY2025, down 0.1% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $20.86B.
▸ Source: FMP /cash-flow-statement · US GAAP · AbbVie Inc. · AbbVie Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026